Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse tra...
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
- Conditions
- Interventions
Study of Anti-HIV Therapy Intensification
- Conditions
- First Posted Date
- 2002-04-23
- Last Posted Date
- 2012-05-18
- Target Recruit Count
- 22
- Registration Number
- NCT00034086
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 15
- Registration Number
- NCT00000772
- Locations
- 🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸University of Minnesota, ACTU, Minneapolis, Minnesota, United States
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 110
- Registration Number
- NCT00000923
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 12
- Registration Number
- NCT00000839
- Locations
- 🇺🇸
Columbia IMPAACT CRS, New York, New York, United States
🇵🇷San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico
🇵🇷Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 440
- Registration Number
- NCT00000885
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 34
- Registration Number
- NCT00000891
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Immunobiology Research Institute
- Registration Number
- NCT00002109
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Fisher Med Group, Phoenix, Arizona, United States
🇺🇸Ctr for Special Immunology, New York, New York, United States
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 390
- Registration Number
- NCT00000814
- Locations
- 🇺🇸
Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States
🇺🇸Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States
🇺🇸Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States
A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 85
- Registration Number
- NCT00000823
- Locations
- 🇺🇸
Illinois Masonic Med Ctr, Chicago, Illinois, United States
🇺🇸Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
🇺🇸Univ of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.